Метионин ПЕТ, обнаруженный при диагностике опухолей мозга и неопухолей: доклад одного центра по 426 случаям.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shiba Yoshiki, Aoki Kosuke, Ohka Fumiharu, Deguchi Shoichi, Yamaguchi Junya, Shimizu Hiroki, Maeda Sachi, Takido Yuhei, Yamamoto Ryo, Nakamura Akihiro, Saito Ryuta
Аннотация
Оригинал публикации
Methionine PET Findings in the Diagnosis of Brain Tumors and Nontumorous Mass Lesions: A Single-Center Report on 426 Cases.
BACKGROUND AND PURPOSE: Differentiating between a brain tumor and a nontumorous lesion remains a diagnostic challenge, particularly when conventional imaging modalities such as CT and MRI provide inconclusive results. While 11C-methionine PET (MET-PET) has shown potential in neuro-oncology, its diagnostic performance across a broad spectrum of brain pathologies has not been comprehensively evaluated. This study, therefore, assessed the sensitivity, specificity, and uptake patterns of MET-PET in a large cohort of brain lesions.
MATERIALS AND METHODS: This single-center retrospective study analyzed 426 consecutive patients with undiagnosed brain lesions who underwent MET-PET imaging between January 2019 and May 2024. Tumor-to-normal region ratios (TNRs) were calculated by using a threshold of 1.5 for positive findings. Histologic diagnoses were established on the basis of the World Health Organization 2021 criteria, including isocitrate dehydrogenase (IDH) mutation status and 1p/19q-codeletion.
RESULTS: Among the cohort, 342 cases (67.8%) were confirmed as having tumorous lesions; 76 (17.8%), as having nontumorous lesions; and 61 (14.3%) remained undiagnosed. MET-PET exhibited high sensitivity (86.2%) but limited specificity (47.4%) for tumor detection. In multiple sclerosis cases, MET-PET showed a remarkably high positivity rate (n = 10/12) that was significantly higher than for other nontumorous lesions. In terms of tumors, IDH wild-type glioblastomas had significantly higher TNRs compared with IDH-mutant gliomas, while oligodendrogliomas had higher TNRs compared with astrocytomas, in which TNR values correlated with tumor grade.
CONCLUSIONS: MET-PET demonstrated robust sensitivity for brain tumor detection but was limited by low specificity due to false-positives in inflammatory conditions and false-negatives for low-grade tumors. These findings imply the importance of integrating MET-PET with other imaging modalities to enhance diagnostic accuracy.